Stock Scorecard



Stock Summary for Pacira BioSciences Inc (PCRX) - $17.03 as of 11/20/2024 8:34:09 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PCRX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PCRX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PCRX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PCRX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PCRX (38 out of 90)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 6
Book Value to Price (Max of 10) 2
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 3
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0

Latest News for for PCRX

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee 11/14/2024 3:05:00 PM
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth 11/7/2024 3:09:00 PM
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 10/30/2024 12:00:00 PM
Are Options Traders Betting on a Big Move in Pacira BioSciences ( PCRX ) Stock? 10/21/2024 12:38:00 PM
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer 10/21/2024 12:00:00 PM
Pacira's Exparel Receives Permanent New Product-Specific J-Code 10/4/2024 3:12:00 PM
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 - Pacira BioSciences ( NASDAQ:PCRX ) 10/3/2024 12:00:00 PM
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 10/3/2024 12:00:00 PM
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee 9/26/2024 12:00:00 PM
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee - Pacira BioSciences ( NASDAQ:PCRX ) 9/26/2024 12:00:00 PM

Financial Details for PCRX

Company Overview

Ticker PCRX
Company Name Pacira BioSciences Inc
Country USA
Description Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 17.03
Price 4 Years Ago 59.84
Last Day Price Updated 11/20/2024 8:34:09 PM EST
Last Day Volume 466,592
Average Daily Volume 564,184
52-Week High 35.95
52-Week Low 11.16
Last Price to 52 Week Low 52.60%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE 16.07
Free Cash Flow Ratio 1.73
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 2.25
Total Cash Per Share 9.83
Book Value Per Share Most Recent Quarter 16.24
Price to Book Ratio 1.02
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 1.11
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 46,173,200
Market Capitalization 786,329,596
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -24.50%
Annual Earnings Growth 163.72%
Reported EPS 12 Trailing Months -1.98
Reported EPS Past Year 2.30
Reported EPS Prior Year 2.92
Net Income Twelve Trailing Months -98,759,000
Net Income Past Year 41,955,000
Net Income Prior Year 15,909,000
Quarterly Revenue Growth YOY 2.80%
5-Year Revenue Growth 13.54%
Operating Margin Twelve Trailing Months 0.13

Balance Sheet

Total Cash Most Recent Quarter 453,810,000
Total Cash Past Year 278,581,000
Total Cash Prior Year 288,651,000
Net Cash Position Most Recent Quarter -133,547,000
Net Cash Position Past Year -243,856,000
Long Term Debt Past Year 522,437,000
Long Term Debt Prior Year 689,471,000
Total Debt Most Recent Quarter 587,357,000
Equity to Debt Ratio Past Year 0.62
Equity to Debt Ratio Most Recent Quarter 0.56
Total Stockholder Equity Past Year 870,130,000
Total Stockholder Equity Prior Year 775,010,000
Total Stockholder Equity Most Recent Quarter 749,583,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -8,463,000
Free Cash Flow Per Share Twelve Trailing Months -0.18
Free Cash Flow Past Year 139,488,000
Free Cash Flow Prior Year 115,198,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.27
MACD Signal 0.38
20-Day Bollinger Lower Band 10.87
20-Day Bollinger Middle Band 16.56
20-Day Bollinger Upper Band 22.24
Beta 0.82
RSI 48.27
50-Day SMA 24.66
150-Day SMA 40.71
200-Day SMA 45.94

System

Modified 11/19/2024 9:50:29 AM EST